European Journal of Epidemiology

, Volume 19, Issue 4, pp 353–363 | Cite as

The 23-Valent Pneumococcal Polysaccharide Vaccine. Part I. Efficacy of PPV in the Elderly: A Comparison of Meta-Analyses

  • Alessia Melegaro
  • W. John Edmunds

Abstract

A 23-valent polysaccharide pneumococcal vaccine (PPV) has been available in the UK for more than 20 years and is currently recommended for use in high-risk groups (HRG) of 2+ years of age. The degree of protection afforded by the PPV remains a critical issue, although a number of randomised clinical trials and case–control studies (CCS) have been published. The aim of this work is to review the estimates on the efficacy of PPV against pneumococcal pneumonia and invasive pneumococcal disease (IPD) in the elderly and to perform a meta-analysis in order to obtain a pooled estimate of the level of protection in high and low risk individuals. These two groups of individuals are at the centre of the current debate on whether or not to extend the vaccination programme to all elderly individuals 65+. Only randomised and quasi-randomised studies are included in the analysis and results are compared with previous meta-analyses. The effect of the inclusion of observational studies is investigated in the sensitivity analysis. When taken with the results of other meta-analyses and observational studies, it appears that PPV offers protection against IPD in the general elderly population (VE = 65%; 95% CI:−49–92%) whereas it has a moderate effect in the high-risk elderly (VE = 20%; 95% CI:−188–78%). The vaccine has little or no effect against pneumonia (VE = 16% in the general elderly and −20% in HRG).

Elderly High-risk Meta-analysis Polysaccharide pneumococcal vaccine (PPV) Vaccine efficacy (VE) 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    CDC. Prevention of pneumococcal disease: Recommendations of the advisory committee on immunisation practices (ACIP). MMWR 1997; 46(RR-08): 1-24.Google Scholar
  2. 2.
    Obaro SK, Monteil MA, Henderson DC. Fortnightly review: The pneumococcal problem. Br Med J 1996; 312: 1521.Google Scholar
  3. 3.
    Ortqvist A. Pneumococcal vaccination: Current and future issues. Eur Resp J 2001; 18: 184-195.Google Scholar
  4. 4.
    Salisbury DM, Begg NT. Immunisation against infectious disease, Bicentenary Edition. London: HMSO, 1996.Google Scholar
  5. 5.
    Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA et al. Efficacy of pneumococcal vaccination in adults — A meta analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-2677.PubMedGoogle Scholar
  6. 6.
    Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1.Google Scholar
  7. 7.
    Hutchinson BG, Oxman AD, Shannon HS, Lioyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine — Meta-analysis. Can Family Physician 1999; 45: 2381-2393.Google Scholar
  8. 8.
    Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: A metaanalysis of randomized trials. Vaccine 2001; 19: 4780-4790.PubMedGoogle Scholar
  9. 9.
    Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharide after pneumococcal vaccination. Infect Immun 1999; 67: 5979-5984.PubMedGoogle Scholar
  10. 10.
    Leinonen M, Syrjala H, Jalonen E, Kujala P, Herva E. Demonstration of pneumolysin antibodies in circulating immune complexes — a new diagnostic method for pneumococcal pneumonia. Serodiag Immunother Inf Dis 1990; 4: 451-458.Google Scholar
  11. 11.
    Jadad A. Assessing the quality of reports of RCTs: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.PubMedGoogle Scholar
  12. 12.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.PubMedGoogle Scholar
  13. 13.
    Johan Giesecke. Modern Infectious Disease Epidemiology. London: Edward Arnold, 1994.Google Scholar
  14. 14.
    Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. JAMA 1994; 272: 1367-1371.PubMedGoogle Scholar
  15. 15.
    Kaufman P. Pneumonia in old age. Active immunisation against pneumonia with pneumococcus polysaccharide. Results of a six year study. Arch Intern Med 1947; 518-531.Google Scholar
  16. 16.
    Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP et al. Essai clinique du vaccin antipneumococcique chez des personnes agees vivant en institution. Rev Epidem Sante Publ 1985; 33: 437-444.Google Scholar
  17. 17.
    Honkanen P, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among elderly persons aged 65 years or older. Vaccine 1999; 17: 2493-2500.PubMedGoogle Scholar
  18. 18.
    Klastersky J, Mommen P, Cantraine F, Safary A. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol 1986; 22: 807-813.PubMedGoogle Scholar
  19. 19.
    Koivula I, Sten M, Leinonen M, Makela H. Clinical efficacy of pneumococcal vaccine in the elderly: A randomized, single-blind population-based trial. Am J Med 1997; 103: 281-290.PubMedGoogle Scholar
  20. 20.
    Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vacination Study Group. Lancet 1998; 351(9100): 399-403.PubMedGoogle Scholar
  21. 21.
    Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease — a pilot study. Chest 1987; 92: 204-212.PubMedGoogle Scholar
  22. 22.
    Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL. Efficacy of pneumococcal vaccine in high-risk patients — results of a veterans administration cooperative study. N Engl J Med 1986; 315: 1318-1327.PubMedGoogle Scholar
  23. 23.
    Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987; 136: 361-365.PubMedGoogle Scholar
  24. 24.
    Riley ID, Andrews M, Howard R, Tarr PI, Pfeiffer M, Challands P. Immunisation with a polyvalent pneumococcal vaccine. Lancet 1977; 1338-1341.Google Scholar
  25. 25.
    Smit P, Oberholzer D, Hayden-Smith S. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238: 2613-2616.PubMedGoogle Scholar
  26. 26.
    Austrian R, Douglas RM, Schiffman G. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physician 1976; 89: 184-194.Google Scholar
  27. 27.
    Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of penumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101: 325-330.PubMedGoogle Scholar
  28. 28.
    Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-1460.PubMedGoogle Scholar
  29. 29.
    Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-657.PubMedGoogle Scholar
  30. 30.
    Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995; 155: 2336-2340.PubMedGoogle Scholar
  31. 31.
    Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommandations. JAMA 1993; 270: 1826-1831.PubMedGoogle Scholar
  32. 32.
    Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in high-risk population. Am J Med 1987; 83: 425-430.PubMedGoogle Scholar
  33. 33.
    Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF 3rd. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104: 1-6.PubMedGoogle Scholar
  34. 34.
    Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333-1339.PubMedGoogle Scholar
  35. 35.
    Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A et al. Cost-effectiveness of pneumococcal vaccination of older people: A study in 5 European countries. Clin Inf Dis 2000; 31: 444-450.Google Scholar
  36. 36.
    Claxton K, Neumann PJ, Araki S, Weinstein M. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. Intern J Technol Assess Health Care 2001; 17: 38-55.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Alessia Melegaro
    • 1
  • W. John Edmunds
    • 2
  1. 1.Department of Biological SciencesUniversity of WarwickLondonUK; Health Protection Agency, Communicable Disease Surveillance Centre, Modelling and Economics Unit, 61 Colindale Avenue, London NW9 5EQ, UK; Phone:
  2. 2.Modelling and Economics UnitHPA Communicable Disease Surveillance CentreLondonUK; Department of Economics, City University, London, UK

Personalised recommendations